SARS-CoV-2 vaccines, breakthrough SARS-CoV-2 infection, correlates of protection, hematological malignancies, allogeneic stem cell transplantation, autologous stem cell transplantation, COVID-19, vaccine, immunocompromised patients, Moderna mRNA-1273, Pfiz
Aspergillus, pulmonary aspergillosis, mannoprotein, Galactomannan, lateral flow immunoassay, Platelia® Galactomannan immunoassay, Virclia® Galactomannan monotest
SARS-CoV-2, COVID-19 vaccine, T-cell immunity, anti-RBD antibodies, booster